<DOC>
	<DOCNO>NCT00424749</DOCNO>
	<brief_summary>Churg-Strauss Syndrome ( CSS ) disease characterize asthma , abnormally high amount eosinophil ( type white blood cell ) , blood vessel inflammation . About 25 % CSS patient develop kidney disease . The goal pilot study evaluate safety effectiveness Rituximab induce remission kidney disease patient CSS .</brief_summary>
	<brief_title>Rituxan Churg Strauss Syndrome With Renal Involvement</brief_title>
	<detailed_description>Churg-Strauss syndrome ( CSS ) small vessel systemic vasculitis associate asthma eosinophilia cause glomerulonephritis 25 % patient . Rituximab chimeric anti-CD20 monoclonal antibody deplete B cell effective numerous autoimmune disease include antineutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis . The aim study evaluate safety efficacy Rituximab induce remission renal disease activity patient CSS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients ChurgStrauss syndrome define meet one 3 set criteria ChurgStrauss Syndrome describe yet treat , fail steroid therapy ( partial nonresponders ) taper oral prednisone document relapse disease Renal involvement ( &gt; 25 % dysmorphic red cell , red blood cell cast , pauciimmune glomerulonephritis biopsy ) Age &gt; 18 year old Serum creatinine less equal 3.0 mg/dl Able willing give write informed consent comply requirement study protocol . Negative serum pregnancy test ( woman child bear age ) Men woman reproductive potential must agree use acceptable method birth control treatment twelve month completion treatment . Exclusion Criteria Severe obstructive restrictive lung disease ( forced expiratory volume one second &lt; 1 ) Cerebral involvement Rapidly progressive optic neuropathy retinal vasculitis Active gastrointestinal bleeding Heart failure , include pericarditis myocarditis . Hemoglobin &lt; 8.5 gm/dL Platelets &lt; 100,000/mm AST ALT &gt; 2.5 Upper Limit Normal unless related primary disease Positive Hepatitis B C serology History positive HIV test Treatment investigational agent within 4 week screen 5 halflives investigational drug ( whichever longer ) Previous treatment Rituximab History severe allergic anaphylactic reaction humanize murine monoclonal antibody History recurrent significant infection history recurrent bacterial infection Known active bacterial , viral fungal mycobacterial , infection ( include tuberculosis atypical mycobacterial disease , exclude fungal infection nail bed ) major episode infection require hospitalization treatment i.v . antibiotic within 4 week screen oral antibiotic within 2 week prior screen Lack peripheral venous access History drug , alcohol , chemical abuse within 6 month prior screen Pregnancy lactation Concomitant malignancies previous malignancy , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Antineutrophil cytoplasmic antibody associate vasculitis</keyword>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Rituximab</keyword>
</DOC>